A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, double-blind, multiple cohort, fixed-dose multiple
crossover, dose-finding study of oral BTD-001 in adult patients with IH or Narcolepsy without
cataplexy (Type 2).